| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Papillomavirus Infections | 38 | 2023 | 363 | 5.710 |
Why?
|
| Papillomaviridae | 22 | 2018 | 136 | 3.680 |
Why?
|
| Liver Neoplasms | 18 | 2025 | 211 | 3.210 |
Why?
|
| Carcinoma, Hepatocellular | 17 | 2025 | 158 | 3.190 |
Why?
|
| Breast Neoplasms | 23 | 2024 | 1679 | 2.430 |
Why?
|
| Ovarian Neoplasms | 16 | 2025 | 406 | 1.920 |
Why?
|
| Middle Aged | 92 | 2025 | 11819 | 1.910 |
Why?
|
| Aged | 79 | 2025 | 7982 | 1.860 |
Why?
|
| Neoplasms | 15 | 2024 | 1341 | 1.680 |
Why?
|
| Female | 121 | 2025 | 24018 | 1.630 |
Why?
|
| Areca | 3 | 2025 | 33 | 1.570 |
Why?
|
| Registries | 20 | 2025 | 431 | 1.570 |
Why?
|
| Humans | 153 | 2025 | 42163 | 1.530 |
Why?
|
| Hawaii | 38 | 2025 | 2004 | 1.500 |
Why?
|
| Cyanobacteria | 2 | 2023 | 26 | 1.490 |
Why?
|
| Thyroid Neoplasms | 5 | 2024 | 49 | 1.470 |
Why?
|
| Uterine Cervical Diseases | 6 | 2012 | 14 | 1.360 |
Why?
|
| Adult | 68 | 2025 | 13458 | 1.320 |
Why?
|
| Incidence | 29 | 2025 | 1054 | 1.280 |
Why?
|
| SEER Program | 18 | 2024 | 157 | 1.250 |
Why?
|
| Mouth Neoplasms | 3 | 2020 | 60 | 1.250 |
Why?
|
| Cohort Studies | 33 | 2025 | 1729 | 1.180 |
Why?
|
| Mammary Glands, Human | 3 | 2018 | 40 | 1.180 |
Why?
|
| Papillomavirus Vaccines | 6 | 2021 | 168 | 1.170 |
Why?
|
| Uterine Cervical Neoplasms | 10 | 2023 | 350 | 1.160 |
Why?
|
| Carcinoma, Squamous Cell | 10 | 2020 | 187 | 1.130 |
Why?
|
| Anus Diseases | 5 | 2012 | 17 | 1.120 |
Why?
|
| Risk Factors | 36 | 2025 | 3942 | 1.090 |
Why?
|
| Male | 68 | 2025 | 22779 | 1.050 |
Why?
|
| Body Mass Index | 6 | 2025 | 916 | 1.010 |
Why?
|
| Alphapapillomavirus | 7 | 2015 | 30 | 0.990 |
Why?
|
| Cystadenocarcinoma, Serous | 6 | 2024 | 44 | 0.980 |
Why?
|
| Laryngeal Neoplasms | 3 | 2016 | 13 | 0.980 |
Why?
|
| DNA, Viral | 14 | 2019 | 323 | 0.960 |
Why?
|
| Gene Expression | 4 | 2018 | 692 | 0.900 |
Why?
|
| Microcystins | 2 | 2023 | 8 | 0.890 |
Why?
|
| Case-Control Studies | 20 | 2025 | 1266 | 0.830 |
Why?
|
| Aged, 80 and over | 23 | 2025 | 2803 | 0.830 |
Why?
|
| Cervix Uteri | 6 | 2013 | 47 | 0.800 |
Why?
|
| United States | 34 | 2025 | 5072 | 0.800 |
Why?
|
| Survival Analysis | 12 | 2023 | 362 | 0.800 |
Why?
|
| Bacterial Toxins | 1 | 2023 | 50 | 0.780 |
Why?
|
| Carcinoma, Papillary | 2 | 2024 | 15 | 0.730 |
Why?
|
| Genitalia, Male | 3 | 2013 | 14 | 0.730 |
Why?
|
| Carcinoma, Ductal | 1 | 2021 | 5 | 0.730 |
Why?
|
| Mouth | 1 | 2021 | 49 | 0.710 |
Why?
|
| Anus Neoplasms | 6 | 2019 | 43 | 0.700 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2016 | 471 | 0.680 |
Why?
|
| Relaxin | 1 | 2020 | 10 | 0.680 |
Why?
|
| Hypothyroidism | 1 | 2020 | 25 | 0.670 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2020 | 24 | 0.670 |
Why?
|
| Human papillomavirus 16 | 8 | 2021 | 37 | 0.660 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 3 | 2018 | 32 | 0.660 |
Why?
|
| Specimen Handling | 3 | 2015 | 61 | 0.660 |
Why?
|
| Colorectal Neoplasms | 7 | 2024 | 502 | 0.660 |
Why?
|
| Prognosis | 15 | 2024 | 850 | 0.640 |
Why?
|
| Prevalence | 16 | 2021 | 1597 | 0.590 |
Why?
|
| Vimentin | 1 | 2018 | 38 | 0.590 |
Why?
|
| Obesity | 3 | 2025 | 1131 | 0.570 |
Why?
|
| Skin Neoplasms | 4 | 2025 | 175 | 0.570 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2018 | 100 | 0.560 |
Why?
|
| Prostatic Neoplasms | 6 | 2024 | 1068 | 0.560 |
Why?
|
| Inflammation Mediators | 1 | 2018 | 138 | 0.540 |
Why?
|
| Mouth Diseases | 1 | 2017 | 5 | 0.530 |
Why?
|
| Melanoma | 4 | 2023 | 109 | 0.520 |
Why?
|
| Mutation | 3 | 2020 | 1169 | 0.520 |
Why?
|
| Young Adult | 17 | 2025 | 4936 | 0.510 |
Why?
|
| Vaccination | 2 | 2010 | 332 | 0.510 |
Why?
|
| Precancerous Conditions | 1 | 2017 | 83 | 0.490 |
Why?
|
| Pancreatic Neoplasms | 5 | 2024 | 206 | 0.490 |
Why?
|
| Immunocompromised Host | 4 | 2025 | 26 | 0.490 |
Why?
|
| Saliva | 1 | 2017 | 115 | 0.490 |
Why?
|
| Adolescent | 18 | 2025 | 5950 | 0.480 |
Why?
|
| Genotype | 12 | 2021 | 796 | 0.470 |
Why?
|
| Immunohistochemistry | 11 | 2019 | 928 | 0.470 |
Why?
|
| Carcinoma | 3 | 2022 | 106 | 0.460 |
Why?
|
| Receptors, Somatomedin | 1 | 2015 | 3 | 0.460 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2015 | 3 | 0.460 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2015 | 27 | 0.460 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2023 | 744 | 0.450 |
Why?
|
| Cross-Sectional Studies | 7 | 2025 | 3077 | 0.450 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2015 | 81 | 0.440 |
Why?
|
| Head and Neck Neoplasms | 3 | 2021 | 81 | 0.430 |
Why?
|
| Neoplasm Staging | 10 | 2020 | 366 | 0.430 |
Why?
|
| Lymphoma, Non-Hodgkin | 4 | 2018 | 40 | 0.430 |
Why?
|
| Polyomavirus Infections | 2 | 2025 | 18 | 0.430 |
Why?
|
| Neoplasm Invasiveness | 6 | 2016 | 284 | 0.420 |
Why?
|
| Virus Diseases | 2 | 2022 | 27 | 0.420 |
Why?
|
| Micronutrients | 3 | 2010 | 45 | 0.420 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2024 | 60 | 0.410 |
Why?
|
| Hepatitis B, Chronic | 1 | 2013 | 16 | 0.410 |
Why?
|
| Adenocarcinoma, Mucinous | 3 | 2019 | 24 | 0.400 |
Why?
|
| Self Administration | 1 | 2013 | 67 | 0.400 |
Why?
|
| Hepatitis C, Chronic | 1 | 2013 | 44 | 0.400 |
Why?
|
| Penile Neoplasms | 3 | 2015 | 12 | 0.400 |
Why?
|
| Proportional Hazards Models | 13 | 2024 | 512 | 0.390 |
Why?
|
| Antigens, Viral | 1 | 2012 | 50 | 0.380 |
Why?
|
| Anal Canal | 3 | 2010 | 32 | 0.370 |
Why?
|
| Virion | 1 | 2012 | 73 | 0.370 |
Why?
|
| Circumcision, Male | 2 | 2010 | 8 | 0.370 |
Why?
|
| Mastication | 2 | 2025 | 24 | 0.370 |
Why?
|
| Capsid Proteins | 1 | 2012 | 74 | 0.370 |
Why?
|
| Postmenopause | 5 | 2025 | 139 | 0.360 |
Why?
|
| Oropharyngeal Neoplasms | 4 | 2015 | 10 | 0.350 |
Why?
|
| Health Status Disparities | 3 | 2019 | 705 | 0.350 |
Why?
|
| Retrospective Studies | 10 | 2025 | 2485 | 0.350 |
Why?
|
| Organ Transplantation | 5 | 2025 | 26 | 0.350 |
Why?
|
| Body Height | 2 | 2021 | 53 | 0.350 |
Why?
|
| Carcinoma, Merkel Cell | 2 | 2025 | 3 | 0.340 |
Why?
|
| Sexual Behavior | 4 | 2021 | 634 | 0.330 |
Why?
|
| Substance Abuse, Intravenous | 2 | 2022 | 128 | 0.330 |
Why?
|
| Penile Diseases | 1 | 2010 | 6 | 0.330 |
Why?
|
| Health Promotion | 1 | 2016 | 691 | 0.330 |
Why?
|
| Ultraviolet Rays | 2 | 2025 | 118 | 0.330 |
Why?
|
| Antibodies, Viral | 1 | 2012 | 295 | 0.320 |
Why?
|
| Parity | 2 | 2024 | 60 | 0.320 |
Why?
|
| Survival Rate | 5 | 2024 | 353 | 0.320 |
Why?
|
| RNA, Ribosomal, 16S | 3 | 2021 | 190 | 0.320 |
Why?
|
| Mammography | 3 | 2018 | 211 | 0.310 |
Why?
|
| Odds Ratio | 6 | 2021 | 587 | 0.310 |
Why?
|
| Adenocarcinoma | 6 | 2021 | 287 | 0.310 |
Why?
|
| BRCA1 Protein | 2 | 2024 | 58 | 0.310 |
Why?
|
| Guam | 2 | 2021 | 83 | 0.310 |
Why?
|
| Receptors, Progesterone | 4 | 2025 | 90 | 0.300 |
Why?
|
| Neoplasm Proteins | 4 | 2024 | 228 | 0.300 |
Why?
|
| Weight Gain | 1 | 2009 | 138 | 0.290 |
Why?
|
| Hydroxycholesterols | 2 | 2025 | 18 | 0.280 |
Why?
|
| Tissue Array Analysis | 8 | 2020 | 79 | 0.280 |
Why?
|
| Population Surveillance | 4 | 2017 | 245 | 0.270 |
Why?
|
| Sexual Partners | 2 | 2008 | 325 | 0.270 |
Why?
|
| Tumor Virus Infections | 1 | 2007 | 22 | 0.270 |
Why?
|
| Heterosexuality | 1 | 2008 | 96 | 0.270 |
Why?
|
| Keratins | 2 | 2018 | 25 | 0.270 |
Why?
|
| Receptors, Estrogen | 3 | 2025 | 177 | 0.270 |
Why?
|
| Liver Diseases | 3 | 2016 | 34 | 0.260 |
Why?
|
| Vulvar Neoplasms | 3 | 2016 | 10 | 0.260 |
Why?
|
| Receptors, Androgen | 2 | 2025 | 144 | 0.250 |
Why?
|
| BRCA2 Protein | 2 | 2024 | 50 | 0.250 |
Why?
|
| DNA Methylation | 4 | 2024 | 393 | 0.240 |
Why?
|
| Oncogene Proteins, Viral | 2 | 2023 | 25 | 0.240 |
Why?
|
| Physician's Role | 1 | 2006 | 39 | 0.240 |
Why?
|
| Estrogen Receptor alpha | 2 | 2025 | 120 | 0.240 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2024 | 25 | 0.230 |
Why?
|
| Longitudinal Studies | 6 | 2013 | 1020 | 0.230 |
Why?
|
| Intermediate Filament Proteins | 1 | 2005 | 16 | 0.230 |
Why?
|
| Sexually Transmitted Diseases | 2 | 2023 | 172 | 0.230 |
Why?
|
| Genomics | 2 | 2024 | 289 | 0.230 |
Why?
|
| Prospective Studies | 9 | 2024 | 1574 | 0.230 |
Why?
|
| HIV Infections | 5 | 2025 | 2535 | 0.230 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2024 | 11 | 0.230 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2025 | 57 | 0.230 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2025 | 53 | 0.230 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2024 | 2 | 0.220 |
Why?
|
| Diet Surveys | 2 | 2009 | 97 | 0.220 |
Why?
|
| Self Care | 1 | 2006 | 173 | 0.220 |
Why?
|
| Keratin-7 | 2 | 2019 | 4 | 0.220 |
Why?
|
| Vitamin B Complex | 1 | 2003 | 5 | 0.210 |
Why?
|
| Privacy | 1 | 2023 | 7 | 0.210 |
Why?
|
| Disease Progression | 2 | 2024 | 661 | 0.210 |
Why?
|
| Phytoestrogens | 1 | 2004 | 40 | 0.210 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2023 | 233 | 0.210 |
Why?
|
| Adiposity | 1 | 2025 | 155 | 0.210 |
Why?
|
| Gonorrhea | 1 | 2023 | 24 | 0.210 |
Why?
|
| MicroRNAs | 2 | 2020 | 501 | 0.200 |
Why?
|
| Transcription Factors | 4 | 2022 | 722 | 0.200 |
Why?
|
| BK Virus | 1 | 2023 | 4 | 0.200 |
Why?
|
| Recurrence | 2 | 2021 | 149 | 0.200 |
Why?
|
| Marine Toxins | 1 | 2023 | 17 | 0.200 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2023 | 19 | 0.200 |
Why?
|
| Follow-Up Studies | 4 | 2020 | 1051 | 0.200 |
Why?
|
| Age Factors | 6 | 2024 | 1139 | 0.190 |
Why?
|
| Stomach Neoplasms | 2 | 2021 | 228 | 0.190 |
Why?
|
| Time Factors | 6 | 2015 | 1848 | 0.190 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2016 | 959 | 0.190 |
Why?
|
| Liver Transplantation | 2 | 2020 | 37 | 0.190 |
Why?
|
| Tocopherols | 3 | 2013 | 61 | 0.190 |
Why?
|
| Paraffin Embedding | 3 | 2021 | 13 | 0.190 |
Why?
|
| Formaldehyde | 3 | 2021 | 30 | 0.190 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2023 | 84 | 0.190 |
Why?
|
| Dietary Supplements | 1 | 2003 | 208 | 0.180 |
Why?
|
| Biomedical Research | 2 | 2019 | 467 | 0.180 |
Why?
|
| Sepsis | 1 | 2022 | 90 | 0.180 |
Why?
|
| Chlamydia Infections | 1 | 2023 | 199 | 0.180 |
Why?
|
| Early Detection of Cancer | 4 | 2019 | 428 | 0.180 |
Why?
|
| Drug Users | 1 | 2022 | 51 | 0.180 |
Why?
|
| Risk | 4 | 2015 | 289 | 0.180 |
Why?
|
| Carotenoids | 3 | 2012 | 74 | 0.180 |
Why?
|
| Cholangiocarcinoma | 1 | 2021 | 7 | 0.180 |
Why?
|
| Rural Population | 1 | 2024 | 352 | 0.170 |
Why?
|
| Medicare | 2 | 2021 | 326 | 0.170 |
Why?
|
| Laboratories | 1 | 2021 | 40 | 0.170 |
Why?
|
| Asia | 1 | 2021 | 99 | 0.170 |
Why?
|
| Cystadenoma, Serous | 1 | 2020 | 1 | 0.170 |
Why?
|
| Organ Specificity | 1 | 2020 | 141 | 0.170 |
Why?
|
| Endometriosis | 1 | 2022 | 81 | 0.170 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 93 | 0.160 |
Why?
|
| Immunotherapy | 1 | 2021 | 137 | 0.160 |
Why?
|
| Tissue Fixation | 2 | 2021 | 18 | 0.160 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2020 | 59 | 0.160 |
Why?
|
| California | 4 | 2024 | 531 | 0.160 |
Why?
|
| Massachusetts | 3 | 2024 | 35 | 0.160 |
Why?
|
| Matrix Attachment Region Binding Proteins | 1 | 2019 | 5 | 0.160 |
Why?
|
| Research | 1 | 2021 | 177 | 0.150 |
Why?
|
| Warts | 2 | 2011 | 5 | 0.150 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2024 | 933 | 0.150 |
Why?
|
| Pilot Projects | 3 | 2024 | 733 | 0.150 |
Why?
|
| Prostate | 2 | 2023 | 152 | 0.150 |
Why?
|
| Uterine Cervical Dysplasia | 2 | 2013 | 41 | 0.150 |
Why?
|
| Behavioral Research | 1 | 2019 | 41 | 0.150 |
Why?
|
| Rectal Neoplasms | 1 | 2018 | 19 | 0.150 |
Why?
|
| Opioid-Related Disorders | 1 | 2022 | 188 | 0.150 |
Why?
|
| Penis | 2 | 2010 | 90 | 0.150 |
Why?
|
| Lymphocytes | 1 | 2019 | 124 | 0.140 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2024 | 181 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2018 | 41 | 0.140 |
Why?
|
| Receptor, erbB-2 | 2 | 2018 | 149 | 0.140 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2018 | 6 | 0.140 |
Why?
|
| Tongue Neoplasms | 1 | 2018 | 9 | 0.140 |
Why?
|
| Minority Health | 1 | 2019 | 96 | 0.140 |
Why?
|
| Neutrophils | 1 | 2019 | 141 | 0.140 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2018 | 15 | 0.140 |
Why?
|
| Adenocarcinoma, Clear Cell | 2 | 2020 | 20 | 0.140 |
Why?
|
| Metabolome | 1 | 2018 | 50 | 0.140 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2018 | 31 | 0.140 |
Why?
|
| Ovary | 1 | 2018 | 112 | 0.140 |
Why?
|
| National Cancer Institute (U.S.) | 3 | 2024 | 32 | 0.140 |
Why?
|
| Neoplastic Stem Cells | 1 | 2018 | 94 | 0.140 |
Why?
|
| Cause of Death | 2 | 2015 | 183 | 0.140 |
Why?
|
| Tissue Banks | 3 | 2024 | 9 | 0.140 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2018 | 64 | 0.140 |
Why?
|
| Actinomyces | 1 | 2017 | 5 | 0.130 |
Why?
|
| Streptococcus | 1 | 2017 | 18 | 0.130 |
Why?
|
| Food | 1 | 2018 | 102 | 0.130 |
Why?
|
| Vulva | 1 | 2016 | 3 | 0.130 |
Why?
|
| Inflammation | 2 | 2020 | 729 | 0.130 |
Why?
|
| Hepatitis | 1 | 2016 | 11 | 0.130 |
Why?
|
| Benzamides | 2 | 2014 | 78 | 0.130 |
Why?
|
| Telomere | 1 | 2016 | 59 | 0.120 |
Why?
|
| Family Practice | 1 | 2016 | 57 | 0.120 |
Why?
|
| Sex Factors | 3 | 2016 | 1008 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2023 | 150 | 0.120 |
Why?
|
| RNA, Neoplasm | 1 | 2015 | 25 | 0.120 |
Why?
|
| DNA, Neoplasm | 1 | 2015 | 92 | 0.120 |
Why?
|
| Logistic Models | 6 | 2014 | 1001 | 0.110 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2015 | 61 | 0.110 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2015 | 28 | 0.110 |
Why?
|
| Coffee | 1 | 2014 | 20 | 0.110 |
Why?
|
| Photosensitizing Agents | 1 | 2015 | 55 | 0.110 |
Why?
|
| Vaginal Neoplasms | 1 | 2014 | 1 | 0.110 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2015 | 83 | 0.110 |
Why?
|
| Immunosuppressive Agents | 1 | 2015 | 94 | 0.110 |
Why?
|
| Superoxide Dismutase | 1 | 2015 | 158 | 0.110 |
Why?
|
| Calcifediol | 1 | 2014 | 17 | 0.110 |
Why?
|
| Diabetes Complications | 1 | 2014 | 99 | 0.110 |
Why?
|
| Hepatitis B Core Antigens | 1 | 2013 | 3 | 0.100 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2013 | 13 | 0.100 |
Why?
|
| Hepatitis B virus | 1 | 2013 | 18 | 0.100 |
Why?
|
| Risk Assessment | 4 | 2023 | 845 | 0.100 |
Why?
|
| Minority Groups | 1 | 2019 | 663 | 0.100 |
Why?
|
| Multivariate Analysis | 4 | 2019 | 638 | 0.100 |
Why?
|
| Piperazines | 1 | 2014 | 117 | 0.100 |
Why?
|
| Herpesvirus 4, Human | 1 | 2013 | 36 | 0.100 |
Why?
|
| Burkitt Lymphoma | 1 | 2013 | 25 | 0.100 |
Why?
|
| Hepacivirus | 1 | 2013 | 73 | 0.100 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2013 | 25 | 0.100 |
Why?
|
| Health Services Accessibility | 2 | 2024 | 680 | 0.100 |
Why?
|
| Pyrimidines | 1 | 2014 | 130 | 0.100 |
Why?
|
| Comorbidity | 3 | 2016 | 725 | 0.100 |
Why?
|
| Choline Kinase | 1 | 2012 | 2 | 0.100 |
Why?
|
| Hexokinase | 1 | 2012 | 10 | 0.100 |
Why?
|
| Adiponectin | 1 | 2013 | 59 | 0.100 |
Why?
|
| Carcinoma in Situ | 1 | 2012 | 16 | 0.100 |
Why?
|
| Erythrocyte Membrane | 1 | 2012 | 20 | 0.100 |
Why?
|
| Matrix Metalloproteinases | 1 | 2012 | 49 | 0.100 |
Why?
|
| Samoa | 1 | 2012 | 16 | 0.100 |
Why?
|
| Neutralization Tests | 1 | 2012 | 55 | 0.090 |
Why?
|
| Microspheres | 1 | 2012 | 49 | 0.090 |
Why?
|
| C-Reactive Protein | 1 | 2013 | 164 | 0.090 |
Why?
|
| Immunoassay | 1 | 2012 | 69 | 0.090 |
Why?
|
| Cytokinesis | 1 | 2011 | 10 | 0.090 |
Why?
|
| Leptin | 1 | 2013 | 118 | 0.090 |
Why?
|
| Endometrial Neoplasms | 1 | 2013 | 79 | 0.090 |
Why?
|
| Fatty Acids | 1 | 2012 | 134 | 0.090 |
Why?
|
| Condylomata Acuminata | 1 | 2011 | 6 | 0.090 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2011 | 69 | 0.090 |
Why?
|
| Hepatitis B | 2 | 2016 | 41 | 0.090 |
Why?
|
| Los Angeles | 4 | 2014 | 390 | 0.090 |
Why?
|
| Prions | 1 | 2011 | 23 | 0.090 |
Why?
|
| Feeding Behavior | 1 | 2014 | 461 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 456 | 0.090 |
Why?
|
| Poisson Distribution | 3 | 2015 | 44 | 0.090 |
Why?
|
| Vaginal Smears | 2 | 2017 | 62 | 0.080 |
Why?
|
| Foreskin | 1 | 2010 | 4 | 0.080 |
Why?
|
| Confidence Intervals | 3 | 2016 | 162 | 0.080 |
Why?
|
| Membrane Proteins | 1 | 2014 | 548 | 0.080 |
Why?
|
| Gene Expression Profiling | 2 | 2024 | 683 | 0.080 |
Why?
|
| Hepatitis C | 2 | 2016 | 138 | 0.080 |
Why?
|
| Mice | 6 | 2018 | 6490 | 0.080 |
Why?
|
| Cell Cycle Proteins | 1 | 2011 | 239 | 0.080 |
Why?
|
| Proctitis | 1 | 2009 | 2 | 0.080 |
Why?
|
| Cytokines | 1 | 2013 | 661 | 0.080 |
Why?
|
| Protein Array Analysis | 2 | 2005 | 27 | 0.070 |
Why?
|
| Animals | 8 | 2018 | 16695 | 0.070 |
Why?
|
| Soy Foods | 1 | 2009 | 60 | 0.070 |
Why?
|
| Anticarcinogenic Agents | 1 | 2009 | 74 | 0.070 |
Why?
|
| Smoking | 3 | 2017 | 1019 | 0.070 |
Why?
|
| Disease Transmission, Infectious | 1 | 2008 | 30 | 0.070 |
Why?
|
| Nutritional Status | 1 | 2009 | 115 | 0.070 |
Why?
|
| RNA, Messenger | 2 | 2022 | 1265 | 0.070 |
Why?
|
| Phenotype | 2 | 2025 | 774 | 0.070 |
Why?
|
| Cell Line, Tumor | 4 | 2018 | 2598 | 0.070 |
Why?
|
| Semen | 1 | 2008 | 55 | 0.070 |
Why?
|
| Breast | 1 | 2009 | 139 | 0.070 |
Why?
|
| Down-Regulation | 2 | 2020 | 452 | 0.070 |
Why?
|
| Treatment Outcome | 3 | 2017 | 1586 | 0.070 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2020 | 222 | 0.070 |
Why?
|
| Condoms | 1 | 2008 | 148 | 0.070 |
Why?
|
| Vitamin A | 1 | 2007 | 85 | 0.060 |
Why?
|
| DNA-Binding Proteins | 2 | 2022 | 557 | 0.060 |
Why?
|
| Gene Regulatory Networks | 2 | 2018 | 143 | 0.060 |
Why?
|
| Healthcare Disparities | 1 | 2012 | 573 | 0.060 |
Why?
|
| Bacteria | 2 | 2021 | 285 | 0.060 |
Why?
|
| Diagnosis, Differential | 2 | 2019 | 236 | 0.060 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 979 | 0.060 |
Why?
|
| Epidemiologic Research Design | 1 | 2005 | 18 | 0.060 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2025 | 25 | 0.060 |
Why?
|
| Keratin-20 | 1 | 2005 | 2 | 0.060 |
Why?
|
| Mice, Nude | 2 | 2018 | 403 | 0.060 |
Why?
|
| Herpesviridae Infections | 1 | 2005 | 18 | 0.060 |
Why?
|
| Alcohol Drinking | 2 | 2016 | 585 | 0.060 |
Why?
|
| Disease-Free Survival | 2 | 2015 | 116 | 0.060 |
Why?
|
| Sarcoma, Kaposi | 1 | 2005 | 24 | 0.060 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2005 | 20 | 0.060 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2025 | 11 | 0.060 |
Why?
|
| Organizational Case Studies | 1 | 2024 | 31 | 0.060 |
Why?
|
| Social Marketing | 1 | 2004 | 25 | 0.060 |
Why?
|
| Promoter Regions, Genetic | 2 | 2018 | 534 | 0.060 |
Why?
|
| DNA Copy Number Variations | 1 | 2024 | 37 | 0.060 |
Why?
|
| Mass Media | 1 | 2004 | 38 | 0.060 |
Why?
|
| Medical Record Linkage | 1 | 2024 | 16 | 0.060 |
Why?
|
| Philippines | 1 | 2024 | 80 | 0.060 |
Why?
|
| Menarche | 1 | 2024 | 15 | 0.050 |
Why?
|
| Reproductive History | 1 | 2024 | 27 | 0.050 |
Why?
|
| Pregnancy | 2 | 2024 | 1737 | 0.050 |
Why?
|
| Menopause | 1 | 2024 | 63 | 0.050 |
Why?
|
| Germ-Line Mutation | 1 | 2024 | 74 | 0.050 |
Why?
|
| Thiamine | 1 | 2003 | 6 | 0.050 |
Why?
|
| Ovariectomy | 1 | 2024 | 128 | 0.050 |
Why?
|
| Riboflavin | 1 | 2003 | 24 | 0.050 |
Why?
|
| Genetic Testing | 1 | 2024 | 90 | 0.050 |
Why?
|
| Confidentiality | 1 | 2023 | 27 | 0.050 |
Why?
|
| Women's Health | 1 | 2004 | 158 | 0.050 |
Why?
|
| Socioeconomic Factors | 1 | 2008 | 1221 | 0.050 |
Why?
|
| Vitamin B 12 | 1 | 2003 | 23 | 0.050 |
Why?
|
| Iowa | 2 | 2016 | 9 | 0.050 |
Why?
|
| Folic Acid | 1 | 2003 | 49 | 0.050 |
Why?
|
| Antioxidants | 1 | 2007 | 439 | 0.050 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2024 | 90 | 0.050 |
Why?
|
| Antigens, Viral, Tumor | 1 | 2023 | 8 | 0.050 |
Why?
|
| Mortality | 1 | 2005 | 174 | 0.050 |
Why?
|
| Genes, p53 | 1 | 2023 | 28 | 0.050 |
Why?
|
| Interviews as Topic | 1 | 2024 | 428 | 0.050 |
Why?
|
| Biopsy | 1 | 2003 | 176 | 0.050 |
Why?
|
| Cluster Analysis | 1 | 2023 | 206 | 0.050 |
Why?
|
| Aneuploidy | 2 | 2014 | 24 | 0.050 |
Why?
|
| Oncogene Proteins | 1 | 2022 | 22 | 0.050 |
Why?
|
| Patient Selection | 1 | 2004 | 192 | 0.050 |
Why?
|
| Cyclin E | 1 | 2022 | 14 | 0.050 |
Why?
|
| Glycolysis | 1 | 2023 | 71 | 0.050 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2022 | 27 | 0.050 |
Why?
|
| Genome-Wide Association Study | 1 | 2024 | 421 | 0.050 |
Why?
|
| Testosterone | 1 | 2023 | 211 | 0.050 |
Why?
|
| Prostate-Specific Antigen | 1 | 2023 | 145 | 0.050 |
Why?
|
| Forkhead Transcription Factors | 1 | 2022 | 75 | 0.050 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2022 | 9 | 0.050 |
Why?
|
| Universities | 1 | 2006 | 539 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2019 | 602 | 0.050 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2023 | 160 | 0.050 |
Why?
|
| Trust | 1 | 2023 | 157 | 0.050 |
Why?
|
| Chronic Disease | 2 | 2016 | 541 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2018 | 1804 | 0.050 |
Why?
|
| Harm Reduction | 1 | 2022 | 27 | 0.050 |
Why?
|
| Qualitative Research | 1 | 2024 | 526 | 0.050 |
Why?
|
| Mice, SCID | 2 | 2012 | 158 | 0.050 |
Why?
|
| Waist-Hip Ratio | 1 | 2021 | 34 | 0.050 |
Why?
|
| Canada | 1 | 2022 | 157 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2021 | 50 | 0.040 |
Why?
|
| Housing | 1 | 2022 | 68 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2018 | 1554 | 0.040 |
Why?
|
| Pathology | 1 | 2021 | 8 | 0.040 |
Why?
|
| Data Collection | 1 | 2002 | 210 | 0.040 |
Why?
|
| Neoplasm, Residual | 1 | 2020 | 15 | 0.040 |
Why?
|
| Brain Neoplasms | 1 | 2022 | 129 | 0.040 |
Why?
|
| Gene Knockout Techniques | 1 | 2020 | 54 | 0.040 |
Why?
|
| Disease Outbreaks | 1 | 2021 | 169 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2021 | 336 | 0.040 |
Why?
|
| Phosphorylation | 2 | 2014 | 973 | 0.040 |
Why?
|
| Nuclear Proteins | 1 | 2022 | 330 | 0.040 |
Why?
|
| Appendiceal Neoplasms | 1 | 2019 | 3 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 1058 | 0.040 |
Why?
|
| Body Weight | 1 | 2021 | 428 | 0.040 |
Why?
|
| Proliferating Cell Nuclear Antigen | 2 | 2009 | 49 | 0.040 |
Why?
|
| Poly(A)-Binding Proteins | 1 | 2018 | 9 | 0.040 |
Why?
|
| Overweight | 1 | 2021 | 248 | 0.040 |
Why?
|
| Hep G2 Cells | 1 | 2018 | 62 | 0.040 |
Why?
|
| In Situ Hybridization | 1 | 2018 | 134 | 0.040 |
Why?
|
| Research Support as Topic | 1 | 2019 | 89 | 0.040 |
Why?
|
| Blood Proteins | 1 | 2018 | 75 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2018 | 139 | 0.040 |
Why?
|
| Computational Biology | 1 | 2020 | 324 | 0.040 |
Why?
|
| Risk-Taking | 1 | 2021 | 456 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 233 | 0.040 |
Why?
|
| Graft Rejection | 1 | 2018 | 43 | 0.030 |
Why?
|
| Viral Envelope Proteins | 1 | 2018 | 90 | 0.030 |
Why?
|
| HIV Seropositivity | 1 | 2019 | 196 | 0.030 |
Why?
|
| Metabolomics | 1 | 2018 | 90 | 0.030 |
Why?
|
| Micronesia | 1 | 2017 | 87 | 0.030 |
Why?
|
| Research Personnel | 1 | 2019 | 191 | 0.030 |
Why?
|
| alpha-Fetoproteins | 1 | 2017 | 31 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2003 | 479 | 0.030 |
Why?
|
| Cultural Diversity | 1 | 2019 | 187 | 0.030 |
Why?
|
| Hyperlipidemias | 1 | 2017 | 47 | 0.030 |
Why?
|
| Algorithms | 1 | 2020 | 508 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2018 | 686 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2018 | 140 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2017 | 132 | 0.030 |
Why?
|
| Liver Cirrhosis | 1 | 2017 | 64 | 0.030 |
Why?
|
| International Classification of Diseases | 1 | 2016 | 28 | 0.030 |
Why?
|
| Central America | 1 | 2016 | 11 | 0.030 |
Why?
|
| South America | 1 | 2016 | 22 | 0.030 |
Why?
|
| Demography | 1 | 2016 | 195 | 0.030 |
Why?
|
| Latin America | 1 | 2016 | 53 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2018 | 267 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2016 | 102 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2018 | 658 | 0.030 |
Why?
|
| Genome, Human | 1 | 2016 | 143 | 0.030 |
Why?
|
| Human papillomavirus 18 | 1 | 2015 | 6 | 0.030 |
Why?
|
| Feces | 1 | 2016 | 126 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 53 | 0.030 |
Why?
|
| Remission Induction | 1 | 2015 | 19 | 0.030 |
Why?
|
| Azathioprine | 1 | 2015 | 5 | 0.030 |
Why?
|
| Animals, Newborn | 1 | 2016 | 350 | 0.030 |
Why?
|
| Cyclosporine | 1 | 2015 | 36 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2016 | 203 | 0.030 |
Why?
|
| Mexico | 1 | 2016 | 286 | 0.030 |
Why?
|
| Florida | 1 | 2016 | 461 | 0.030 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2015 | 43 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 2015 | 165 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2014 | 62 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 2014 | 8 | 0.030 |
Why?
|
| Cell Division | 1 | 2015 | 314 | 0.030 |
Why?
|
| Educational Status | 1 | 2016 | 335 | 0.030 |
Why?
|
| Cell Growth Processes | 1 | 2014 | 43 | 0.030 |
Why?
|
| Myosin Type II | 1 | 2014 | 15 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 508 | 0.030 |
Why?
|
| 25-Hydroxyvitamin D 2 | 1 | 2014 | 8 | 0.030 |
Why?
|
| Molecular Epidemiology | 1 | 2014 | 58 | 0.030 |
Why?
|
| Subcellular Fractions | 1 | 2014 | 79 | 0.030 |
Why?
|
| Community-Based Participatory Research | 1 | 2017 | 336 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 577 | 0.030 |
Why?
|
| Sunlight | 1 | 2014 | 48 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2014 | 137 | 0.030 |
Why?
|
| Genes, bcl-2 | 1 | 2013 | 7 | 0.030 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 2013 | 13 | 0.030 |
Why?
|
| Genes, myc | 1 | 2013 | 30 | 0.030 |
Why?
|
| Mass Screening | 1 | 2017 | 531 | 0.030 |
Why?
|
| Tanzania | 1 | 2013 | 26 | 0.020 |
Why?
|
| Japan | 1 | 2014 | 348 | 0.020 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2012 | 6 | 0.020 |
Why?
|
| RNA | 1 | 2015 | 266 | 0.020 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2012 | 16 | 0.020 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2012 | 26 | 0.020 |
Why?
|
| Viral Structural Proteins | 1 | 2012 | 17 | 0.020 |
Why?
|
| Histocytochemistry | 1 | 2012 | 47 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2012 | 51 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2015 | 884 | 0.020 |
Why?
|
| Microscopy | 1 | 2012 | 33 | 0.020 |
Why?
|
| Life Style | 1 | 2014 | 326 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2012 | 84 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2012 | 99 | 0.020 |
Why?
|
| Triglycerides | 1 | 2012 | 146 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2015 | 518 | 0.020 |
Why?
|
| Oncogenes | 1 | 2011 | 44 | 0.020 |
Why?
|
| Quinazolines | 1 | 2011 | 37 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2013 | 317 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 438 | 0.020 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2011 | 61 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2013 | 458 | 0.020 |
Why?
|
| Cell Movement | 1 | 2015 | 640 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2012 | 454 | 0.020 |
Why?
|
| Cholesterol | 1 | 2012 | 230 | 0.020 |
Why?
|
| Mitosis | 1 | 2011 | 112 | 0.020 |
Why?
|
| Lipids | 1 | 2012 | 256 | 0.020 |
Why?
|
| Histones | 1 | 2011 | 194 | 0.020 |
Why?
|
| Chromatin | 1 | 2011 | 179 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 532 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2011 | 348 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2013 | 960 | 0.020 |
Why?
|
| Infant | 1 | 2013 | 1143 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2018 | 2111 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2012 | 534 | 0.020 |
Why?
|
| Estrogen Receptor beta | 1 | 2009 | 39 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2009 | 64 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2009 | 34 | 0.020 |
Why?
|
| Premenopause | 1 | 2009 | 109 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2013 | 1516 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 310 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2009 | 190 | 0.020 |
Why?
|
| Diet | 1 | 2013 | 810 | 0.020 |
Why?
|
| Child | 1 | 2013 | 3381 | 0.010 |
Why?
|
| Rats | 1 | 2012 | 3701 | 0.010 |
Why?
|
| Aging | 1 | 2009 | 764 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2009 | 1420 | 0.010 |
Why?
|
| Motivation | 1 | 2004 | 492 | 0.010 |
Why?
|